Immunogenicity of a booster of BNT162b2 vaccine in healthcare workers
- Dagan N
- Barda N
- et al.
and 94-95% effectiveness in real world studies in Israel.
- Haas EJ
- Angulo FJ
- McLaughlin JM
- et al.
Similar efficacy rates (97% against symptomatic infection and 86% against asymptomatic infection) were found among health workers.
- Angel Y
- Spitzer A
- Henig O
- et al.
The declining efficacy of the vaccine, alongside the spread of the delta variant (B.1.617.2), prompted the Israeli Ministry of Health to recommend, in early August 2021, a booster dose for people aged 60 and over. years or older who received a second dose. vaccine at least 5 months earlier.
Here we report the effect of a third dose of BNT162b2 on anti-SARS-CoV-2 IgG concentrations in employees of the Tel Aviv medical center, vaccinated between August 1 and August 18, 2021. The concentrations of anti-spike proteins were established with the ADVIA Centaur SARS-CoV-2 IgG test, which provides an index value up to 150.00, where an index equal to or greater than 1.00 is considered reactive (positive) for SARS-CoV-2 IgG antibodies. The study was approved by the Institutional Review Board of the Tel Aviv Medical Center (approval number TLV-21-0576).
- VG room
- Ferreira VH
- Ku T
- et al.
- Kamar N
- Abravanel F
- Marion O
- Couat C
- Izopet J
- Del Bello A
To our knowledge, this work is the largest report of a third dose of BNT162b2 vaccine in healthcare workers. Our results show high immunoreactivity of the vaccine in healthcare workers, who are generally immunocompetent. Further follow-up is necessary to determine the effect of a third dose on clinical outcomes such as symptomatic illness, hospitalization, and death.
We do not declare any competing interests.
BNT162b2 Covid-19 mRNA vaccine in a nationwide mass vaccination setting.
N Engl J Med. 2021; 384: 1412-1423
Impact and efficacy of the BNT162b2 mRNA vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalizations and deaths following a national vaccination campaign in Israel: an observational study using national surveillance data.
Lancet. 2021; 397: 1819-1829
Association between vaccination with BNT162b2 and the incidence of symptomatic and asymptomatic SARS-CoV-2 infections in health workers.
JAMA. 2021; 3252457
Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients.
N Engl J Med. 2021; 385: 1244-1246
Three doses of a Covid-19 mRNA vaccine in solid organ transplant recipients.
N Engl J Med. 2021; 385: 661-662
Posted: 11 October 2021
© 2021 The author (s). Posted by Elsevier Ltd.
License to use
For non-commercial purposes:
- Read, print and download
- Redistribute or republish the final article
- Text and data mine
- Translate the article (private use only, not for distribution)
- Reuse portions or extracts of the article in other works
- Sell or reuse for commercial purposes
- Distribute translations or adaptations of the article